243
Participants
Start Date
September 13, 2016
Primary Completion Date
June 27, 2018
Study Completion Date
January 22, 2021
Docetaxel
Docetaxel (75-mg/m\^2) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
Pertuzumab
Pertuzumab (840-mg loading dose for Cycle 1, followed by 420 mg for subsequent cycles) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
Placebo
Placebo matched to pertuzumab was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
Trastuzumab
Trastuzumab (8-mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
CHINESE ACADEMY OF MEDICAL SCIENCE; CANCER INST. & HOSPITAL; Medical ward, Beijing
Beijing Cancer Hospital, Beijing
Chinese PLA General Hospital, Beijing
First Hospital of China Medical University, Shenyang
The 900th Hospital of PLA joint service support force, Fuzhou
Liaoning cancer Hospital & Institute, Shenyang
the First Hospital of Jilin University, Changchun
Harbin Medical University Cancer Hospital, Harbin
Fudan University Shanghai Cancer Center, Shanghai
Jiangsu province hospital; surgery on galactophore, Nanjing
Jiangsu Cancer Hospital, Nanjing
Changzhou First People's Hospital, Changzhou
Zhejiang Cancer Hospital, Zhejiang
Guangdong General Hospital, Guangzhou
West China Hospital, Sichuan University, Chengdu
Hoffmann-La Roche
INDUSTRY